Printer Friendly

Switch to long-acting antipsychotics beneficial.

AT THE ECNP CONGRESS

BERLIN -- A switch to long-acting second-generation injectable antipsychotics brought improved attitudes and beliefs regarding antipsychotic therapy among patients with schizo-affective disorder who already were stabilized on a single oral antipsychotic agent, Dr. Francesco Pietrini reported at the annual congress of the European College of Neuropsychopharmacology.

The conventional view has been that long-acting injectable antipsychotics are most appropriate as an alternative option for patients with poor adherence to oral antipsychotics. But this small observational study suggests that the switch is beneficial in a broader population, according to Dr. Pietrini of the University of Florence (Italy).

The 18 outpatients who participated in this 12-month, prospective, observational study showed significant improvements in many measures of psychopathology after the switch to long-acting injectable therapy. These benefits were accompanied by a steadily improving attitude toward treatment as reflected in rising scores on the Drug Attitude Inventory-10 (DAI-10).

All patients were stable at baseline on either oral olanzapine or oral paliperidone. They were then switched to the corresponding dose of the long-acting injectable formulation of the same drug and followed prospectively for 12 months.

Mean scores on the 0-10 DAI-10 rose from 3.22 at baseline to 6.56 after 6 months on a long-acting injectable antipsychotic and 8.11 at 12 months. These improvements in scores reflect the patients' growing endorsement of inventory items such as "taking medication will prevent me from having a breakdown," "my thoughts are clearer on medication," and "for me, the good things about medication outweigh the bad."

Scores on most measures of psychopathology improved from baseline during the first 6 months on long-acting therapy. The improvement was maintained but not expanded upon during the second 6 months. The exception was negative psychotic symptoms as assessed by the negative symptom scale of the Positive and Negative Syndrome Scale (PANSS), which didn't show significant improvement during the first 6 months but did in the second half of the year-long study (see chart).

VITALS

Key clinical point: A switch to a long-acting injectable antipsychotic proved beneficial in multiple ways in patients with schizoaffective disorder who were stable on a single oral agent.

Major finding: Mean scores on the Drug Attitude Inventory-10 improved from 3.22 when patients were stabilized on an oral antipsychotic to 6.56 after 6 months on the long-term injectable formulation of the same drug and 8.11 after 12 months.

Data source: This was a 12-month observational study of 18 outpatients with schizoaffective disorder.

Disclosures: Dr. Pietrini reported having no financial conflicts regarding this study, which was conducted free of commercial support.

bjancin@frontlinemedcom.com
Switching to injectable therapy: The results

                                      Baseline   6 months   12 months

DAI-10                                   3.22       6.56       8.11
General psychopathology scale of        32.94      20.72      19.78
  PANSS
Positive symptoms scale of PANSS        14.22       8.67       8.61
Negative symptoms scale of PANSS        13.17       9.72       8.39
Montgomery-Asberg Depression Rating     12.72       6.28       4.11
  Scale
Young Mania Rating Scale                 6.94       2.22       1.5

Note: The prospective, observational study involved 18
outpatients.

Source: Dr. Pietrini
COPYRIGHT 2015 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:ADULT PSYCHIATRY
Author:Jancin, Bruce
Publication:Clinical Psychiatry News
Date:Jan 1, 2015
Words:512
Previous Article:Curbside consult: considering patients' family, culture.
Next Article:Genitourinary injuries can cause long-term trauma.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters